Hemolytic anemia due to adenylate kinase deficiency
MONDO:0012967Hemolytic anemia due to adenylate kinase deficiency is a rare hemolytic anemia due to an erythrocyte nucleotide metabolism disorder characterized by moderate to severe chronic nonspherocytic hemolytic anemia that may require regular blood transfusions and/or splenectomy and may be associated with psychomotor impairment.
Also known as: adenylate kinase deficiency, hemolytic anaemia due to, adenylate kinase deficiency, hemolytic anemia due to
20 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New blood treatment could block zika in transfusions
Disease control OngoingThis study tests a special treatment for red blood cells that aims to kill the Zika virus, making transfusions safer. About 692 people who need blood transfusions will receive either treated or standard blood. The goal is to see if the treated blood works just as well and is safe…
Phase: PHASE3 • Sponsor: Cerus Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cord blood matching method could expand transplant access for blood cancer patients
Disease control OngoingThis study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 26, 2026 13:02 UTC